Unity Biotechnology (UBX) Stock Statistics & Valuation Metrics

Unity Biotechnology has a market cap or net worth of $19.28M. The enterprise value is $23.19M.

Unity Biotechnology has 17,212,172 shares outstanding. The number of shares has decreased by -2.65% in one year.

Unity Biotechnology’s return on equity (ROE) is -4.00 and return on invested capital (ROIC) is -109.75%.

The current PE Ratio of Unity Biotechnology is -0.63. Unity Biotechnology’s PEG ratio is 0.01.

In the last 12 months, Unity Biotechnology had revenue of 0.00 and earned -25.99M in profits. Earnings per share was -1.54.

In the last 12 months, operating cash flow was -22.04M and capital expenditures 0.00, giving a free cash flow of -22.04M billion.

Unity Biotechnology pays an annual dividend of ―, resulting in a dividend yield of ―

Unity Biotechnology upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.

Unity Biotechnology as a current ratio of 2.62, with Debt / Equity ratio of -9110.73%

In the past 12 months, Unity Biotechnology has paid 0.00 in taxes.

Unity Biotechnology EV to EBITDA ratio is -1.29, with an EV/FCF ratio of -1.55.

Unity Biotechnology has $16.93M in cash and marketable securities with $18.68M in debt, giving a net cash position of $1.74M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Unity Biotechnology is $4.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy